Literature DB >> 15802913

Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Lukas Cepek1, Petra Steinacker, Brit Mollenhauer, Birgitt Wiese, Barbara Ciesielczyk, Mirko Bibl, Jens Wiltfang, Inga Zerr, Walter Schulz-Schaeffer, Hans A Kretzschmar, Sigrid Poser, Markus Otto.   

Abstract

BACKGROUND: S-100B and tau protein have a high differential diagnostic potential for the diagnosis of Creutzfeldt-Jakob disease (CJD). So far there has been only limited information available about the dynamics of these parameters in the cerebrospinal fluid (CSF). However, there is a special interest in finding biochemical markers to monitor disease progression for differential diagnosis and treatment. PATIENTS AND METHODS: We analyzed CSF of 45 patients with CJD and of 45 patients with other neurological diseases for tau protein and S-100B in a follow-up setting. All diagnoses of CJD were later neuropathologically verified. A ratio between tau protein differences and the time between lumbar puncture was calculated. The same was done for S-100B.
RESULTS: Tau protein levels of 34 cases were above the cut-off level for CJD (>1,300 pg/ml) in the first CSF sample. In 7 of 11 patients with lower tau levels in the first CSF sample, tau levels rose. The above-mentioned ratio was significantly higher in the CJD group than in the group with other neurological diseases. Similar results were obtained for S-100B.
CONCLUSION: We conclude that follow-up investigations and calculation of ratios is a useful tool in the differential diagnosis of CJD. Variations in this pattern were observed in single cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802913     DOI: 10.1159/000084708

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  4 in total

1.  Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel.

Authors:  Zeev Meiner; Esther Kahana; Fanny Baitcher; Amos D Korczyn; Joab Chapman; Oren S Cohen; Ron Milo; Judith Aharon-Perez; Oded Abramsky; Ruth Gabizon; Hanna Rosenmann
Journal:  J Neurol       Date:  2010-09-09       Impact factor: 4.849

Review 2.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

Review 3.  Biomarkers in dementia: clinical utility and new directions.

Authors:  R M Ahmed; R W Paterson; J D Warren; H Zetterberg; J T O'Brien; N C Fox; G M Halliday; J M Schott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-09-26       Impact factor: 10.154

4.  Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory.

Authors:  Jae Wook Hyeon; Su Yeon Kim; Jeongmin Lee; Jun Sun Park; Kyu Jam Hwang; Sol Moe Lee; SeongSoo A An; Myung Koo Lee; Young Ran Ju
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.